Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Net Cash Flow (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Net Cash Flow data on record, last reported at $53.9 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 229.27% year-over-year to $53.9 million; the TTM value through Dec 2025 reached $42.7 million, up 1767.58%, while the annual FY2025 figure was $42.7 million, 1767.58% up from the prior year.
  • Net Cash Flow reached $53.9 million in Q4 2025 per TNGX's latest filing, up from $19.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $154.1 million in Q3 2021 and bottomed at -$62.2 million in Q4 2021.
  • Average Net Cash Flow over 5 years is $4.2 million, with a median of -$3.8 million recorded in 2022.
  • The widest YoY moves for Net Cash Flow: up 9825.87% in 2021, down 59672.68% in 2021.
  • A 5-year view of Net Cash Flow shows it stood at -$62.2 million in 2021, then soared by 35.17% to -$40.3 million in 2022, then skyrocketed by 119.46% to $7.9 million in 2023, then skyrocketed by 108.63% to $16.4 million in 2024, then surged by 229.27% to $53.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $53.9 million in Q4 2025, $19.1 million in Q3 2025, and -$19.2 million in Q2 2025.